Seer to Report Second Quarter Financial Results on August 12, 2021
Seer, Inc. (Nasdaq: SEER) will announce its Q2 2021 financial results on August 12, 2021, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seer, Inc. (Nasdaq: SEER) will announce its Q2 2021 financial results on August 12, 2021, after market close. A conference call is scheduled for 1:30 PM PT / 4:30 PM ET. Live audio will be available on Seer’s investor website, with replays following the event. The company is known for its Proteograph Product Suite, designed for deep proteomic analysis, revolutionizing research with easy-to-use tools for labs. Seer emphasizes that the Proteograph is for research only and not for diagnostics.
Details
News Market Reaction – SEER
The recorded move for SEER in the trading session of this news was -8.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., July 13, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the second quarter 2021 after market close on Thursday, August 12, 2021. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.
About Seer
Seer is a life sciences company developing transformative products that open up a new gateway to the proteome. Seer is commercializing its Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be adopted by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Investor Contact
Carrie Mendivil
investor@seer.bio
Media Contact
Karen Possemato
pr@seer.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.